htra1a Antibody

What is HTRA1 and why are antibodies against it significant in research?

HTRA1 (High-Temperature Requirement A1), also known as PRSS11, is a 51 kDa serine protease that belongs to the peptidase S1B family . It functions as a protease that regulates the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins and represses signaling by TGF-beta family members . HTRA1 has emerged as an important research target due to its implications in multiple pathological conditions.

The significance of HTRA1 antibodies in research stems from several factors:

• They enable detection and quantification of HTRA1 expression in various tissues and experimental models

• They facilitate investigation of HTRA1's role in diseases including age-related macular degeneration (AMD) and membranous nephropathy

• They provide tools for therapeutic development, as demonstrated by anti-HTRA1 Fab fragments designed to block HTRA1 protease activity in AMD

• They allow monitoring of target engagement and activity in preclinical models and clinical samples

What are the key structural domains of HTRA1 that antibodies might recognize?

HTRA1 contains several functional domains that can serve as antibody recognition sites:

• Signal sequence (SS)

• Insulin-like growth factor binding protein (IGFBP) domain

• Kazal Type I protease inhibitor (KI) domain

• Trypsin-like protease domain

• PDZ binding domain

Different antibodies may target specific domains depending on their intended application. For instance, some polyclonal antibodies are directed against regions in the trypsin-like protease domain , while therapeutic antibodies may target domains critical for enzymatic activity.

What are the optimal conditions for using HTRA1 antibodies in Western blot analysis?

Western blot detection of HTRA1 can be optimized with the following parameters based on established protocols:

For subcellular fractionation studies, nuclear and cytoplasmic fractions should be prepared separately, with beta-actin used as a loading control and DEK (exclusively nuclear) as a fractionation quality control .

What methodologies exist for visualizing HTRA1 expression in tissue samples?

Immunohistochemistry (IHC) and immunofluorescence (IF) techniques have been successfully used to detect HTRA1 in various tissues with the following parameters:

For optimal results, researchers should titrate antibody concentrations based on their specific samples and experimental conditions . In specialized applications such as identifying HTRA1 in membranous nephropathy immune deposits, modifications to standard immunostaining protocols may be necessary .

How can researchers validate the specificity of HTRA1 antibodies?

Multiple validation strategies should be employed to ensure antibody specificity:

• Recombinant protein controls: Test reactivity against recombinant human HTRA1 by Western blot

• Tissue extracts: Confirm detection of HTRA1 at the expected molecular weight (51 kDa) in tissues known to express the protein, such as placenta

• Genetic models: Utilize cell lines with HTRA1 knockdown or overexpression as negative and positive controls, respectively

  • MCF10A/siRNA cell lines with >90% reduction in HTRA1 protein

  • MCF10A/HtrA1 cell line overexpressing HTRA1

• Multiple detection methods: Confirm findings using different techniques (WB, IP, IHC, IF)

• Reducing vs. non-reducing conditions: Verify consistent detection under different conditions

What methods exist for measuring HTRA1 activity rather than merely protein levels?

Several approaches have been developed to assess HTRA1 enzyme activity:

• Activity-based small-molecule probes (ABPs): These probes track target engagement in vivo by binding to active HTRA1

• N-terminomic proteomic profiling: This approach identifies the in vivo repertoire of HTRA1-specific substrates, revealing the enzyme's activity signature

• Substrate cleavage assays: Monitoring cleavage of known HTRA1 substrates such as Dickkopf-related protein 3 (DKK3) provides a quantitative measure of enzyme activity

• Functional inhibition assays: Using HtrA1-blocking Fab fragments to inhibit activity and measuring resulting changes in substrate profiles

• Longitudinal monitoring: Tracking substrate levels in patient samples during active disease versus remission states to correlate with HTRA1 activity

How are HTRA1 antibodies used to investigate age-related macular degeneration (AMD)?

HTRA1 has been implicated in AMD through genetic studies that identified polymorphisms in the HTRA1 promoter region as risk factors for disease development and progression . Researchers have employed HTRA1 antibodies in multiple aspects of AMD research:

• Therapeutic development: HtrA1-blocking Fab fragments have been created to test the hypothesis that inhibiting HTRA1 protease activity could affect AMD progression

• Target engagement assessment: Activity-based probes used in conjunction with antibodies help confirm binding to the intended target in retinal tissue

• Biomarker identification: Anti-HTRA1 antibodies have facilitated the discovery of HtrA1-specific substrates that serve as pharmacodynamic biomarkers, particularly DKK3

• Clinical monitoring: Analysis of HtrA1-mediated cleavage products in the aqueous humor of AMD patients provides evidence of anti-HTRA1 Fab activity and information on therapeutic duration in clinical trials

What is the emerging role of HTRA1 in membranous nephropathy?

Recent research has identified HTRA1 as a novel target podocyte antigen in a subset of patients with primary membranous nephropathy (MN) . Key findings include:

This discovery represents a significant advance in understanding the heterogeneity of membranous nephropathy and suggests new avenues for personalized treatment approaches .

What challenges exist in developing inhibitory antibodies against HTRA1?

Developing effective inhibitory antibodies against HTRA1 presents several technical challenges:

• Structural considerations: Creating antibodies that bind to regions crucial for enzymatic activity without interfering with necessary binding to physiological substrates

• Selectivity issues: Ensuring specificity for HTRA1 without cross-reactivity to related serine proteases in the peptidase S1B family

• Accessibility barriers: Addressing the fact that HTRA1 is found in multiple cellular compartments (nuclear, cytoplasmic) and is also secreted, requiring different targeting strategies depending on the disease mechanism

• Validation complexity: Confirming both target binding and functional inhibition through comprehensive biomarker analysis

• Tissue-specific delivery: Optimizing antibody delivery to relevant tissues (e.g., retina for AMD applications, kidney for nephropathy)

How can researchers distinguish between effects of HTRA1 expression levels versus enzymatic activity?

This important distinction requires careful experimental design:

• Genetic modulation studies: Compare phenotypes between:

  • Knockdown models that reduce HTRA1 protein levels (e.g., MCF10A/siRNA cells)

  • Overexpression models that increase HTRA1 protein (e.g., MCF10A/HtrA1 cells)

• Functional inhibition: Use HtrA1-blocking antibodies that inhibit activity without altering expression levels

• Activity biomarkers: Monitor specific substrate cleavage products (e.g., DKK3) as indicators of enzymatic activity independent of expression levels

• Proteomic analysis: Compare the N-terminomic profiles between models with altered expression versus those with inhibited activity

• Structure-function analysis: Study different HTRA1 domains through truncation mutants or domain-specific antibodies to determine regions crucial for specific functions

What methodological approaches can identify novel HTRA1 substrates in different tissues?

Identifying tissue-specific HTRA1 substrates requires multifaceted approaches:

• N-terminomic proteomic profiling: This technique identifies proteins cleaved by HTRA1 in vivo by capturing the newly generated N-termini resulting from proteolysis

• Comparative analysis with inhibition: Compare substrate profiles in the presence and absence of HtrA1-blocking antibodies to identify specific HTRA1-dependent cleavage events

• Disease-specific sampling: Analyze samples from patients with conditions linked to HTRA1 dysfunction (e.g., AMD, membranous nephropathy) to identify disease-relevant substrates

• Cell-type specific investigations: Examine HTRA1 activity in different cell types relevant to disease (e.g., retinal pigment epithelium for AMD, podocytes for nephropathy)

• Activity-based probes: Use chemical biology approaches to label active HTRA1 and identify associated substrate complexes

How should researchers design experiments to evaluate HTRA1 antibodies in translational models?

A comprehensive evaluation strategy should include:

• Target engagement verification:

  • Activity-based probes to confirm binding to HTRA1 in target tissues

  • Immunohistochemistry to visualize antibody localization

• Functional inhibition assessment:

  • Measurement of substrate cleavage products (e.g., DKK3) in relevant biological fluids

  • Correlation of inhibition with disease-relevant endpoints

• Pharmacokinetic/pharmacodynamic studies:

  • Duration of inhibitory effect following administration

  • Correlation between antibody concentrations and biomarker responses

• Disease model evaluation:

  • Testing in appropriate animal models of AMD or other HTRA1-related conditions

  • Comparing preventive versus therapeutic administration protocols

• Biomarker validation:

  • Confirming that surrogate endpoints (e.g., substrate levels) correlate with clinical outcomes

  • Establishing assays suitable for clinical sample analysis

What emerging technologies might enhance HTRA1 antibody development and application?

Several promising technologies could advance HTRA1 antibody research:

• Single-cell proteomics: To understand cell-specific roles of HTRA1 in heterogeneous tissues

• In situ proximity labeling: To identify context-specific HTRA1 interaction partners and substrates

• Antibody engineering: Development of bispecific antibodies or antibody-drug conjugates for enhanced targeting or function

• Spatial proteomics: To map the tissue distribution of HTRA1 activity with greater precision

• Computational structural biology: To design antibodies with improved specificity and inhibitory properties based on HTRA1's three-dimensional structure